Videos

In addition to the hundreds of sessions and events, ACC has partnered with the World Heart Federation, bringing an international focus to the meeting.

In part 1 of this panel discussion, experts address how they define traditional versus nontraditional oncology pharmacy roles today, as well as the benefits and drawbacks of pursuing such a career path based on their experience.

American College of Cardiology President Edward Fry, MD, FACC, discussed what attendees can look forward to at the 2023 Scientific Sessions.

Dr Haumschild discusses the substantial impact of clinical pathways in the treatment of ovarian cancer.

The significance of multidisciplinary teams in ovarian cancer treatment is highlighted.

David Dalton, PharmD, CEO of Univec, addresses how the pharmacist is ideally positioned to support the technological transformation that is occurring in health care today.

In their closing thoughts, Mr Haumschild leads the panel in a discussion regarding treatments on the horizon for patients with relapsed/refractory multiple myeloma.

Toxicity management associated with anti-CD38 drugs is highlighted by a panel of medical experts.

Brandon Dyson, PharmD, BCOP, BCPS, provides an overview of how tyrosine kinase inhibitor resistance is identified in patients with chronic myeloid leukemia and Philadelphia chromosome-positive ALL.

Experts review how the rates of tyrosine kinase inhibitor resistance affect treatment options for these populations and how to sequence treatment for these patients.

Two members of a clinical-stage authoring group discuss education programs and the alternative career path of medical writing, which can offer hybrid/virtual work-life balance opportunities.

Dr Haumschild explores considerations for safe and appropriate dosing for patients receiving PARP inhibitor therapy.

Ryan Haumschild, PharmD, MS, MBA, opens a discussion surrounding the use of PARP inhibitors within the treatment landscape for ovarian cancer.

Farah Towfic, PharmD, MBA, RPh, director, CEO Operations, US Pharmacopeia, discusses some of the primary topics impacting pharmacists’ delivery of care and quality this year.

Pharmacy technicians and pharmacy technician leadership from UPMC Presbyterian discuss how they became pharmacy technicians in health-system pharmacies.

Current treatment options for depression lead to discontinuation because they are slower to work and have worse adverse event profiles.

Artificial intelligence is allowing researchers to redesign the interaction between the immune system and the protein of an allergen to safely overcome symptoms.

With recent outbreaks of measles and other vaccine-preventable diseases, vaccinations are more important than ever.

Total cost of care for multiple myeloma can be significantly affected by selection of dosing regimen.

Key opinion leaders emphasize the critical role of effective clinical pathways for treatment in multiple myeloma.

In addition to vital historical contributions, pharmacists of color are crucial in reaching marginalized communities and providing culturally competent care.

Brandon Dyson, PharmD, BCOP, BCPS, and Neal Dave, PharmD, explore the unmet needs to address in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive ALL.

Brandon Dyson, PharmD, BCOP, BCPS, discusses the newly released 3-year data from the OPTIC trial, including the study design, baseline characteristics, and efficacy.

This episode features Kathy Pham, PharmD, BCPPS, who discusses her experience at the American College of Clinical Pharmacy (ACCP) and why advocacy is important to health care and the pharmacy profession.

4-drug treatment regimens could provide optimal care strategies for patients with multiple myeloma.

Experts discuss the results of the IKEMA and CANDOR trials.

Experts review the optimal imatinib dosing strategy that is recommended for patients with chronic myeloid leukemia based on the dosing from the IRIS trial.

Neal Dave, PharmD, explores how the generation of the tyrosine kinase inhibitors (TKIs) play a role in treatment selection.

In her closing thoughts, Dr Mahmoudjafari provides an overview of cardiovascular implications associated with CLL as well as the impact of pharmacists in CLL treatment management.

On February 6, 2023, Pharmacy Times also learned that the FDA just accepted a new drug application (NDA) for this treatment.